Regeneron Pharmaceuticals REGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.42B-1.7% | $4.5B+2.1% | $4.58B-1.6% | $4.46B+3.2% | $4.5B+16.6% | ||
| $540M+8.9% | $543.7M+12.6% | $525.1M+11.8% | $510.1M+12.6% | $495.7M+13.8% | ||
| $995.4M-1.3% | $993.7M+1.1% | $1.05B+14.1% | $1.04B+15.5% | $1.01B+15.1% | ||
| —— | —— | —— | —— | $343M+236% | ||
| $98.5M-84.0% | $277.4M-55.2% | $395.1M-28.1% | $476.9M+3.2% | $616.2M+61.9% | ||
| $1.08B+164% | $761.5M+3.6% | $987.1M— | $422.3M— | $410.5M— | ||
| —— | —— | —— | -$82.2M-128% | $149.8M-21.4% | ||
| $5.01B+26.8% | $4.98B+12.6% | $5.07B+19.4% | $4.74B+16.5% | $3.95B-16.6% | ||
| $899.7M+5.7% | $898.4M+18.9% | $849.3M+5.2% | $889.8M+20.0% | $851.3M+26.2% | ||
| —— | —— | —— | —— | —— | ||
| $374.3M+299% | $370.3M— | $277.6M— | $186.4M— | $93.8M— | ||
| $3.19B-4.8% | $3.44B+32.1% | $3.74B+94.9% | $3.81B+120% | $3.35B+84.7% | ||
| $738.4M-12.5% | $635.9M-56.6% | $223.3M-86.7% | $437.7M-74.1% | $843.8M-37.1% | ||
| $601M-12.9% | $532.1M-48.3% | $266.3M-78.4% | $383.5M-69.1% | $689.7M-27.2% | ||
| -$3.43B-2.7% | -$3.72B-68.8% | -$4.07B-169% | -$3.99B-210% | -$3.34B-135% | ||
| —— | —— | —— | $1.1M— | $400K— | ||
| -$122.4M— | $634.7M— | —— | —— | —— | ||
| —— | $41.6M-20.9% | $44.35M-23.2% | $47.1M-25.1% | $49.85M-26.7% | ||
| $742.3M+5.1% | $785.4M+3.7% | $833.1M+9.1% | $723.1M+0.4% | $706M-13.0% | ||
| —— | —— | $513.4M— | —— | —— | ||
| -$187.9M-379% | -$135.5M-275% | -$66.6M-235% | -$21.3M-166% | -$39.2M-290% | ||
| $322M+130% | $315.3M+151% | $340.7M+183% | $297.4M+106% | $140M+3.9% | ||
| —— | —— | —— | —— | -$43.7M— | ||
| $4.11B+32.6% | $4.08B+11.3% | $4.22B+22.7% | $3.85B+15.8% | $3.1B-23.7% | ||
| $4.11B+32.6% | $4.08B+11.3% | $4.22B+22.7% | $3.85B+15.8% | $3.1B-23.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regeneron Pharmaceuticals generate?
- Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.
- What is Regeneron Pharmaceuticals's free cash flow?
- After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.
- Where does Regeneron Pharmaceuticals's cash flow data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
